Journal of Endocrinological Investigation

, Volume 12, Issue 10, pp 739–757 | Cite as

Diagnostic problems in pheochromocytoma

  • M. Mannelli
Review Article


Pheochromocytoma diagnosis catecholamines vanilmandelic acid metanephrines Clonidine glucagon localization 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Manger W.M., Gifford R.W. Pheochromocytoma. Springer-Verlag, New-York, 1977, p. 1.Google Scholar
  2. 2.
    Sullivan S.N., Bloom S.R., Polak J.M. Enkephalin in peripheral neuroendocrine tumors. Lancet 1: 986, 1978.PubMedGoogle Scholar
  3. 3.
    Lundberg J.M., Hamberger B., Shultzberg M., Hoeckfelt T., Gramberg P.O., Efendic S., Terenius L., Goldstein M., Luft R. Enkephalin- and somatostatin-like immunoreactivities in human adrenal medulla and pheochromocytoma. Proc. Natl. Acad. Sci. USA, 76: 4079, 1979.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Gamse R, Saria A., Bucsics A., Lembeck F. Substance P in tumors: pheochromocytoma and carcinoid. Peptides 2 (Suppl. 2): 275, 1981.PubMedGoogle Scholar
  5. 5.
    Faurel J.P., Bernard P., Saigot Th., Bousquet D., Sarrazin A. Phéochromocytome sécrétant du vaso-active intestinal peptide et de la somatostatine. Nouv. Presse Med. 11: 1483, 1982.PubMedGoogle Scholar
  6. 6.
    Sano T., Saito H., Inaba H., Hizawa K., Saito S., Yamanoi A., Mizunuma Y., Matsumura L., Yuasa M., Hiraishi K. Immunoreactive somatostatin and vasoactive intestinal polypeptide in adrenal pheochromocytoma. Cancer 52: 282, 1983.PubMedGoogle Scholar
  7. 7.
    Cubeddu L.S., Wilson S.P., Viveros O.H. Opioid peptides and catecholamines in human pheochromocytoma. Life Sci. 33: 871, 1983.PubMedGoogle Scholar
  8. 8.
    Wu P., Penman E., Coy D.H., Rees L.H. Evidence for direct production of somatostatin 14 from a larger precursor than somatostatin 28 in a pheochromocytoma. Regul. Pept. 5: 219, 1983.PubMedGoogle Scholar
  9. 9.
    Yoshimasa T., Nakao K., Sakamoto M., Suda M., Morii N., Ikeda Y., Ishihara T., Manno M., Hamada S., Shimbo S., Mori T., Yoshimi T., Matsukura S., Imura H. Demonstration and characterization of immunoreactive methionine-enkephalin, leucine-enkephalin, methionine-enkephalin-arg6-gly7-leu8 and methionine-enkephalin-arg6-phe7 in human pheochromocytoma. Acta Endocrinol. (Copenh.) 107: 261, 1984.Google Scholar
  10. 10.
    Cesselin F., Pique L., Bertagna X., Benlot C., Antreassian J., Proeshel M.F., Girard F., Zogbi F., Legrand J.C., Luton J.P., Dauchy J., Tribault J. Simultaneous evaluation of the catecholamine pathway and three opioid peptide producing systems in human pheochromocytomas. Neuropeptides 4: 175, 1984.PubMedGoogle Scholar
  11. 11.
    Baldi E., De Feo M.L., Geppetti P., Carlà V., Maggi M., Pupilli C., Spillantini M.G., Brocchi A., Mannelli M. Measurement of catecholamines, met-enkephalin, somatostatin and substance P-like immunoreactivities in 12 human pheochromocitomas. J. Endocrinol. Invest. 11: 133, 1988.PubMedGoogle Scholar
  12. 12.
    Plouin P.F., Chatellier G., Rougeot M.A., Duclos J.M., Pagny J.Y., Corvol P., Menard J. Recent developments in pheochromocytoma diagnosis and imaging. Adv. Nephrol. 17: 275, 1988.Google Scholar
  13. 13.
    Sjoerdsma A., Engelman K., Waldmann T.A., Cooperman C.H., Hammond W.G. Pheochromocytoma: current concepts of diagnosis and treatment. Ann. Intern. Med. 65: 1302, 1966.Google Scholar
  14. 14.
    Kaplan N.M., Kramer N.J., Holland O.B., Sheps S.G, Gomez-Sanchez C. Single-voided urine methanephrine assay in screening for pheochromocytoma. Arch. Intern. Med. 137: 190, 1977.PubMedGoogle Scholar
  15. 15.
    Feldman J.M., Klatt C. Elevated platelet norepinephrine concentration in patients with pheochromocytomas. Clin. Chim. Acta 117: 279, 1981.PubMedGoogle Scholar
  16. 16.
    Zweifler A.J., Julius S. Increased platelet catecholamine content in pheochromocytoma. N. Engl. J. Med. 306: 890, 1982.PubMedGoogle Scholar
  17. 17.
    Abrams W.B., Solomon H.M. The human platelet as a pharmacologic model for the adrenergic neuron: the uptake and release of norepinephrine. Clin. Pharmacol. Ther. 10: 702, 1969.PubMedGoogle Scholar
  18. 18.
    Pisano J.J., Crout J.R., Abraham D. Determination of 3-methoxy-4-hydroxy-mandelic acid in urine. Clin. Chim. Acta 7: 285, 1962.PubMedGoogle Scholar
  19. 19.
    Felice L.J., Kissinger P.T. A modification of the Pisano method for vanillomandelic acid using high performance liquid chromatography. Clin. Chim. Acta 76: 317, 1977.PubMedGoogle Scholar
  20. 20.
    Gitlow S.E., Mendlowitz M., Bertani L.M. The biochemical techniques for detecting and establishing the presence of a pheochromocytoma. Am. J. Cardiol. 26: 270, 1970.PubMedGoogle Scholar
  21. 21.
    Crout J.R., Pisano J.J. Sjoerdsma A. Urinary excretion of catecholamines and their metabolites in pheochromocytoma. Am. Heart J. 61: 375, 1961.PubMedGoogle Scholar
  22. 22.
    Sheps S.G., Tyce G.M., Flock E.V., Maher F.T. Current experience in the diagnosis of pheochromocytoma. Circulation 34: 473, 1966.PubMedGoogle Scholar
  23. 23.
    Deoreo G.A., Stewart B.M., Tarazi R.C., Gifford R.W. Preoperative blood transfusion in the safe surgical management of pheochromocytoma: a review of 46 cases. J. Urol. 111: 715, 1974.PubMedGoogle Scholar
  24. 24.
    Remine W.H., Chong G.C., Van Heerden J.A., Sheps S.G, Harrison E.G. Current management of pheochromocytoma. Ann. Surg. 179: 740, 1974.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Engelman K. Pheochromocytoma. Clin. Endocrinol. Metab. 6: 769, 1977.PubMedGoogle Scholar
  26. 26.
    Bravo E.L., Tarazi R.C., Gifford R.W., Stewart B.H. Circulating and urinary catecholamines in pheochromocytoma. N. Engl. J. Med. 301: 682, 1979.PubMedGoogle Scholar
  27. 27.
    Jones D.H., Reid J.L., Hamilton C.A., Allison D.J, Welbourn R.B, Dollery C.T. The biochemical diagnosis, localization and follow up of phaeochromocytoma: the role of plasma and urinary catecholamine measurement. Quart. J. Med. 49: 341, 1980.PubMedGoogle Scholar
  28. 28.
    Plouin P.F., Duclos J.M., Menard J., Cornoy E., Bohuon C., Alexandre J.M. Biochemical tests for diagnosis of phaeochromocytoma: urinary versus plasma determination. Br. Med. J. 282: 853, 1981.Google Scholar
  29. 29.
    Van Heerden J.A., Sheps S.G., Hamberger B., Sheedy P.F. II, Poston J.G., Remine W.H. Pheochromocytoma: current status and changing trends. Surgery 91: 367, 1982.PubMedGoogle Scholar
  30. 30.
    Bravo E.L., Gifford R.W. Jr. Pheochromocytoma: diagnosis, localization and management. N. Engl. J. Med. 311: 1298, 1984.PubMedGoogle Scholar
  31. 31.
    Puyo A.M., Levin G.M., Armando I., Barontini M.B. Free and conjugated plasma catecholamines in pheochromocytoma patients with and without sustained hypertension. Acta Endocrinol. (Copenh.) 113: 111, 1986.Google Scholar
  32. 32.
    Mannelli M., De Feo M.L. Maggi M., Pupilli C., Opocher G., Valenza T., Baldi E., Serio M. Usefulness of basal catecholamine plasma levels and Clonidine suppression test in the diagnosis of pheochromocytoma. J. Endocrinol. Invest. 10: 377, 1987.PubMedGoogle Scholar
  33. 33.
    Plouin P.F., Chatellier G., Delahousse M., Rougeot M.A., Duclos J.M., Pagny J.Y., Corvol P., Menard J. Recherche, diagnostique et localisation du phéochromocytome. Presse Med. 16: 2211, 1987.PubMedGoogle Scholar
  34. 34.
    Pisano J.J. A simple analysis for normetanephrine and metanephrine in urine. Clin. Chim. Acta 5: 406, 1960.PubMedGoogle Scholar
  35. 35.
    Sheps S.G., Jiang N.S., Klee G.G. Diagnostic evaluation of pheochromocytoma. Endocrinol. Metab. Clin. North Am. 17: 397, 1988.PubMedGoogle Scholar
  36. 36.
    Oishi S., Sasaki M., Ohno M., Sato T. Urinary normetanephrine and metanephrine measured by radioimmunoassay for the diagnosis of pheochromocytoma: utility of 24-hour and random 1 -hour urine determination. J. Clin. Endocrinol. Metab. 67: 614, 1988.PubMedGoogle Scholar
  37. 37.
    Sullivan J.M., Solomon H.S. The diagnosis of pheochromocytoma. Overnight excretion of catecholamine metabolites. JAMA 231: 618, 1975.PubMedGoogle Scholar
  38. 38.
    Hengstman J.H. Evaluation of screening tests for pheochromocytoma. Cardiology 72 (Suppl. 1): 153, 1986.Google Scholar
  39. 39.
    Nagatsu T. Biochemistry of catecholamines. University Park Press, Baltimore, 1973.Google Scholar
  40. 40.
    Kissinger P.T., Riggin R.M., Alcorn R.L., Rau L.D. Estimation of catecholamines in urine by high performance liquid chromatography with electrochemical detection. Biochem. Med. 13: 299, 1975.PubMedGoogle Scholar
  41. 41.
    Heausler G. Activation of the control pathway of the baroreceptor reflex, a possible mechanism of the hypotensive action of Clonidine. Naunyn Schmiedebergs Arch. Pharmacol. 278: 231, 1973.Google Scholar
  42. 42.
    Hausson B.G., Hoekfelt B. Changes in blood pressure, plasma catecholamines and plasma renin activity during and after treatment with tiamenidine and Clonidine. Br. J. Clin. Pharmacol. 1: 73, 1981.Google Scholar
  43. 43.
    Nilsson A., Hoekfelt B. Effect of dopamine agonist bromocriptine on blood pressure, catecholamines and renin activity in acromegalics at rest, following exercise and during insulin induced hypoglycemia. Acta Endocrinol. (Copenh.) (Suppl. 216): 83, 1978.Google Scholar
  44. 44.
    Ziegler M.G., Lake C.R., Williams A.C., Teychenne P.F., Shoulson I., Stenisland O. Bromocriptine inhibits norepinephrine release. Clin. Pharmacol. Ther. 25: 137, 1979.PubMedGoogle Scholar
  45. 45.
    Langer S.Z. Presynaptic regulation of the release of catecholamines. Pharmacol. Rev. 32: 337, 1981.Google Scholar
  46. 46.
    Fossati P., Fontaine P., Racadot-Leroy N., Decaudaveine B., Wemeau J.L., Proye C. Les catecholamines libres urinaires: dopamine, noradrenaline et adrenaline dans le phéochromocytomes. Rev. Fr. Endocrinol. Clin. 25: 166, 1984.Google Scholar
  47. 47.
    Januszewicz W., Wocial B. Clinical and biochemical aspects of pheocromocytoma. Cardiology 72 (Suppl. 1): 131, 1985.PubMedGoogle Scholar
  48. 48.
    Groendal S., Hamberger B., Telenius-Berg M. Secretory pattern and blood pressure in pheochromocytoma. World J. Surg. 10: 724, 1986.Google Scholar
  49. 49.
    Duncan M.W., Compton P., Lazarus L., Smythe G.A. Measurement of norepinephrine and 3,4-Dihydroxy-phenylglycol in urine and plasma for the diagnosis of pheochromocytoma. N. Engl. J. Med. 319: 136, 1988.PubMedGoogle Scholar
  50. 50.
    Havlik R.J. Cahow C.E., Kinder B.K. Advances in the diagnosis and treatment of pheochromocytoma. Arch. Surg. 123: 626, 1988.PubMedGoogle Scholar
  51. 51.
    Ganguly R., Henry D.P., Yune R.Y, Pratt H., Grim E., Donohue J.P., Weinberger T.H. Diagnosis and localization of pheochromocytoma. Detection by measurement of urinary norepinephrine excretion during sleep, plasma norepinephrine concentration and computerized axial tomography (CT-scan). Am. J. Med. 67: 21, 1979.PubMedGoogle Scholar
  52. 52.
    Louis W.J., Doyle A.E., Heath W.C., Robinson M.J. Secretion of DOPA in pheochromocytoma. Br. Med. J. 4: 325, 1972.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Kuchel O., Buu N.T., Bourque M., Hamet P., Larochelle P. The hemodynamic relevance of free and conjugated dopamine in pheochromocytoma. J. Clin. Endocrinol. Metab. 54: 1268, 1982.PubMedGoogle Scholar
  54. 54.
    Tippet P.A., McEwan A.J., Ackery D.M. A re-evaluation of dopamine excretion in pheochromocytoma. Clin. Endocrinol. 25: 401, 1986.Google Scholar
  55. 55.
    Proye C., Fossati P., Fontaine P., Lefebvre J., Decoulx M., Wemeau J.L., Dewailly D., Rwamasirabo E., Cecat P. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 100: 1155, 1986.Google Scholar
  56. 56.
    Tippet P.A., West R.S., McEwan A.J., Middleton J.E., Ackery D.M. A comparison of dopamine and homovanillic acid excretion as prognostic indicators in malignant phaeochromocytoma. Clin. Chim. Acta 166: 123, 1987.Google Scholar
  57. 57.
    Puyo A., Levin G., Armando I., Barontini M. Total plasma dopamine/norepinephrine ratio in catecholamine-secreting tumors. Its relation to hypertension. Hypertension 11 (Suppl. 1): I–202, 1988.Google Scholar
  58. 58.
    Voorhess M.L., Gardner L.I. Studies of catecholamine excretion by children with neural tumors. J. Clin. Endocrinol. 22: 126, 1962.Google Scholar
  59. 59.
    Goldstein D.S., Stull R., Eisenhofer G., Sisson J.C., Weder A., Auerbuch S.D., Keiser H.R. Plasma 3,4-dihydroxyphenylalanine (DOPA) and catecholamines in neuroblastoma or pheochromocytoma. Ann. Intern. Med. 105: 887, 1986.PubMedGoogle Scholar
  60. 60.
    Wang P.C., Buu N.T., Kuchel O., Genest J. Conjugation patterns of endogenous plasma catecholamines in human and rat. J. Lab. Clin. Med. 101: 141, 1983.PubMedGoogle Scholar
  61. 61.
    Von Euler U.S., Floding I. Fluorimetric micro method for differential estimation of adrenaline and noradrenaline. Acta Physiol. Scand. 33 (Suppl. 118): 45, 1955.Google Scholar
  62. 62.
    Cohen G., Goldenberg M. Simultaneous fluorimetric determination of adrenaline and noradrenaline in plasma. Fluorescence characteristics of adrenaline and noradrenaline and the simultaneous determination in mixtures. J. Neurochem. 2: 58, 1957.PubMedGoogle Scholar
  63. 63.
    Passon P.G., Pauler J.D. A simplified radiometric assay for plasma norepinephrine and epinephrine. Annal. Biochem. 51: 618, 1973.Google Scholar
  64. 64.
    Kissinger P.T. Determination of biogenic amines and their metabolites by liquid chromatography/electrochemistry. In: Parvez S., Nagatsu T., Nagatsu I., Parvez H. (Eds.), Methods in biogenic amines research. Alsevier Science Publisher B.V., Amsterdam, 1983, p. 75.Google Scholar
  65. 65.
    Raum W.J., Swerdloff R.S. A radioimmunoassay for epinephrine and norepinephrine in tissue and plasma. Life Sci. 28: 2819, 1981.PubMedGoogle Scholar
  66. 66.
    Raum W.J. Methods of plasma catecholamine measurement including radioimmunoassay. Am. J. Physiol. 247: E4, 1984.PubMedGoogle Scholar
  67. 67.
    Cryer P.E. Pheochromocytoma Clin. Endocrinol. Metab. 14: 203, 1985.PubMedGoogle Scholar
  68. 68.
    Robertson D., Johnson G.A., Robertson R.M., Nies A.S., Shand D.G., Oates J.A. Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation 59: 637, 1979.PubMedGoogle Scholar
  69. 69.
    Cryer P.E. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. N. Engl. J. Med. 303: 436, 1980.PubMedGoogle Scholar
  70. 70.
    Engelman K., Portnoy B., Sjoerdsma A. Plasma catecholamine concentration in patient with pheochromocytoma. Circ. Res. 26 (Suppl. 1): I141, 1970.Google Scholar
  71. 71.
    Geffen L.B., Rush R.A., Louis W.J., Doyle A.E. Plasma catecholamine and dopamine beta-hydroxylase amounts in phaeochromocytoma. Clin. Sci. 44: 421, 1973.PubMedGoogle Scholar
  72. 72.
    Stewart B.H., Bravo E.L., Meaney T.F. A new simplified approach to the diagnosis of pheochromocytoma. J. Urol. 122: 579, 1979.PubMedGoogle Scholar
  73. 73.
    Sever P.S., Roberts J.C., Snell M.E. Phaeochromocytoma. Clin. Endocrinol. Metab. 9: 543, 1980.PubMedGoogle Scholar
  74. 74.
    Conte-Devolx B., Oliver C., Henry J.F., Aquaron R., Orlando M., Daheme D., Drissi R., Codaccioni J.L. Valeur semeiologique des catécholamines plasmatiques dans le diagnostic de phéochromocytome. Rev. Fr. Endocrinol. Clin. 25: 162, 1984.Google Scholar
  75. 75.
    Kuchel O., Buu N.T., Fontaine A., Hamet P., Beroniade V., Larochelle P., Genest J. Free and conjugated catecholamines in hypertensive patients with and without pheochromocytoma. Hypertension 2: 177, 1986.Google Scholar
  76. 76.
    Brown M.J. Simultaneous assay of noradrenaline and its metabolite dihydroxyphenylglycol in plasma: a simplified approach to the exclusion of pheochromocytoma in patients with borderline elevation of plasma noradrenaline concentration. Eur. J. Clin. Invest. 14: 67, 1984.PubMedGoogle Scholar
  77. 77.
    Lenhert H., Walger P. Plasma 3-methoxy-4-hydroxyphenethylenglicol in pheochromocytoma. Cardiology 72 (Suppl. 1): 160, 1985.Google Scholar
  78. 78.
    O’Connor D.T., Bernstein K.N. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N. Engl. J. Med. 311: 764, 1984.PubMedGoogle Scholar
  79. 79.
    Brown M.J., Allison D.J., Jenner D.A., Lewis P.J., Dollery C.T. Increased sensitivity and accuracy of pheochromocytoma diagnosis achieved by use of plasma-adrenaline estimations and a pentolinium-suppression test. Lancet i: 24, 1981.Google Scholar
  80. 80.
    Bravo E.L., Tarazi C., Fouad M., Vidt G., Gifford W. Jr. Clonidine suppression test. A useful aid in the diagnosis of pheochromocytoma. N. Engl. J. Med. 305: 623, 1981.PubMedGoogle Scholar
  81. 81.
    Lawrence A.M. Glucagon provocative test for pheochromocytoma. Ann. Intern. Med. 66: 1091, 1967.PubMedGoogle Scholar
  82. 82.
    Plouin P.F., Menard J., Corvol P. Hypertensive crisis in patient with pheochromocytoma given metoclopramide. Lancet ii: 1357, 1976.Google Scholar
  83. 83.
    Engelman K., Sjoerdsma A. A new test for pheochromocytoma: pressor responsiveness to tyramine. JAMA 189: 81, 1964.PubMedGoogle Scholar
  84. 84.
    Sheps S.G., Maher F.T. Histamine and glucagon tests in diagnosis of pheochromocytoma. JAMA 205: 895, 1968.PubMedGoogle Scholar
  85. 85.
    Metz S.A., Halter J.B., Porte D. Jr., Robertson R.P. Suppression of plasma catecholamines and flushing by Clonidine in man. J. Clin. Endocrinol. Metab. 46: 83, 1978.PubMedGoogle Scholar
  86. 86.
    Hoekfelt B., Hedeland H., Dymling J.F. Studies on catecholamines, renin and aldosterone following catapressan R [2 (2,6-dichlor-phenyl-amine)-2-imidazoline hydrochloride] in hypertensive patients. Eur. J. Pharmacol. 10: 389, 1970.Google Scholar
  87. 87.
    Elliot W.J., Murphy M.B. Reduced specifity of the Clonidine suppression test in patients with normal plasma catecholamine levels. Am. J. Med. 84: 419, 1988.Google Scholar
  88. 88.
    Brandstetter K., Krause U., Beyer J. Preliminary results with the Clonidine suppression test in the diagnosis of pheochromocytoma. Cardiology 72 (Suppl. 1): 157, 1985.PubMedGoogle Scholar
  89. 89.
    Karlberg B.E., Hedman L. Value of the Clonidine suppression test in the diagnosis of pheochromocytoma. World J. Surg. 10: 753, 1986.PubMedGoogle Scholar
  90. 90.
    Stimpel M., Schuermeyer Th., Ivens K., Wambach G., Volkmann H.P., von zur Muehlen A. Diagnostische Bedeutung des Clonidin-Hemmtests bei Phaeochromozytom-Verdacht. Dtsch. Med. Wochenschr. 113: 130, 1988.PubMedGoogle Scholar
  91. 91.
    Halter J.B., Beard J.C., Pfeifer M.A., Metz S.A. Clonidine-suppression test for diagnosis of pheochromocytoma. N. Engl. J. Med. 306: 49, 1982.Google Scholar
  92. 92.
    Taylor H.C., Mayer D., Anton A.H. Clonidine suppression test for pheochromocytoma: examples of misleading results. J. Clin. Endocrinol. Metab. 63: 238, 1986.PubMedGoogle Scholar
  93. 93.
    Dupont A.G., Vanderniepen P., Gerlo E., Somers G., Vanhaelst L., In’tveld P., Gepts W., Sacre R., Six R.O. Clonidine-suppression test in epinephrine secreting pheochromocytoma: report of a case. J. Endocrinol. Invest 8: 153, 1985.PubMedGoogle Scholar
  94. 94.
    Levinson P.D., Lance B.K., Kowarski A.A., Hamilton B.P. Catecholamine suppression testing in patient with pheochromocytoma and normal plasma catecholamine levels. Lancet i: 1216, 1983.Google Scholar
  95. 95.
    MacDougall I.C., Isles C.G., Stewart H., Inglis G.C., Finlayson J., Thomson I., Lees K.R., McMillon N.C., Morley P., Ball S.G. Overnight Clonidine suppression test in the diagnosis and exclusion of pheochromocytoma. Am. J. Med. 84: 993, 1988.PubMedGoogle Scholar
  96. 96.
    Charney D.S., Heninger G.R., Sternberg D.E. Alpha-2-adrenergic receptor sensitivity and the mechanism of action of antidepressant therapy. Br. J. Psychiatry 142: 265, 1983.PubMedGoogle Scholar
  97. 97.
    Hui T.P., Krakoff L.R., Felton K., Yeager K. Diuretic treatment alters Clonidine suppression of plasma norepinephrine. Hypertension 8: 272, 1986.PubMedGoogle Scholar
  98. 98.
    Lefebvre P.J., Cession-Fossion A., Luyckx A.S. Glucagon test for pheochromocytoma. Lancet ii: 1366,1966.Google Scholar
  99. 99.
    Joasoo A., Freeman Z. Tyramine and glucagon in pheochromocytoma. Lancet ii: 726, 1967.Google Scholar
  100. 100.
    Von Studnitz W. Glukagontest und Pheocromozytomdiagnostik. Schweiz. Med. Wochenschr. 100: 1023, 1970.Google Scholar
  101. 101.
    White L.W., Levy R.P., Anton A.H. Comparison of biochemical and pharmacological testing for pheochromocytoma. Res. Commun. Chem. Pathol. Pharmacol. 5: 252, 1973.PubMedGoogle Scholar
  102. 102.
    Sebel E.F., Hull R.D., Kleerekoper M., Stocks G.S. Responses to glucagon in hypertensive patients with and without pheochromocytoma. Am. J. Med. Sci. 267: 337, 1974.PubMedGoogle Scholar
  103. 103.
    Levinson P.D., Hamilton B.P, Mersey J.H., Kowarski A.A. Plasma norepinephrine and epinephrine responses to glucagon in patients with suspected pheochromocytoma. Metabolism 32: 998, 1983.PubMedGoogle Scholar
  104. 104.
    Goldfien A. Pheochromocytoma. Clin. Endocrinol. Metab. 10: 607, 1981.PubMedGoogle Scholar
  105. 105.
    Scian L.F., Westermann C.D., Verdesca A.S., Hilton J.G. Adrenocortical and medullary effects of glucagon. Am. J. Physiol. 199: 867, 1960.PubMedGoogle Scholar
  106. 106.
    Sarcione E.J., Back N., Sockal J.E., Mehlman B., Knoblock E. Elevation of plasma epinephrine levels produced by glucagon in vivo. Endocrinology 72: 523, 1963.PubMedGoogle Scholar
  107. 107.
    Levey G.S., Weiss S.R., Ruiz E. Characterization of the glucagon receptor in a pheochromocytoma. J. Clin. Endocrinol. Metab. 40: 720, 1975.PubMedGoogle Scholar
  108. 108.
    Kuchel O., Harnet P., Buu N.T., Larochelle P. Basis of false-positive glucagon tests for pheochromocytoma. Clin. Pharmacol. Ther. 29: 687, 1981.PubMedGoogle Scholar
  109. 109.
    Siqueira-Filho A.G., Sheps S.G., Maher F.T., Jiang N.S., Elveback L.R. Glucagon-blood catecholamine test. Use in isolated and familial pheochromocytoma. Arch. Intern. Med. 135: 1227, 1975.PubMedGoogle Scholar
  110. 110.
    Farndon J.R., Dale J.K., Harrison T.S., Seaton J.F., Baylin S.B., Wells S.A. Evaluation of adrenal medullary function in patients with multiple endocrine neoplasia type II (MEN II). World J. Surg. 5: 457, 1981.Google Scholar
  111. 111.
    Engelmann K., Horwitz D., Ambrose I., Sjoerdsma A. Further evaluation of the tyramine test for pheochromocytoma. N. Engl. J. Med. 279: 705, 1968.Google Scholar
  112. 112.
    Agabiti-Rosei E., Alicandri C.L., Corea L. Hypertensive crisis in patients with pheochromocytoma given metoclopramide. Lancet i: 600, 1977.Google Scholar
  113. 113.
    Abe M., Orita Y., Nakashima Y., Nakamura M. Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma. Angiology 35: 122, 1984.PubMedGoogle Scholar
  114. 114.
    Marafelia P., Perrot L., Berthezene F., Mornex R. Valeur semeiologique du test au sulpiride et au glucagon dans le depistage du phéochromocytome. Rev. Fr. Endocrinol. Clin. 27: 197, 1986.Google Scholar
  115. 115.
    Mannelli M, Pupilli C., Forti G. Dopamine and pheochromocytoma. In: Amenta F. (Ed.), Dopamine pathophysiology. CRC Press, Boca Raton, in press.Google Scholar
  116. 116.
    Carney J.A., Sizemore G.W., Tyce G.M. Bilateral adrenal medullary hyperplasia in multiple endocrine neoplasia type 2: the precursor of bilateral pheochromocytoma. Mayo Clin. Proc. 50: 3, 1975.PubMedGoogle Scholar
  117. 117.
    De Lellis R.A., Wolfe H.G., Gagel R.F., Feldman Z.T., Miller H.H., Gang D.L., Reichlin S. Adrenal medullary hyperplasia: a morphometric analysis in patients with familial medullary thyroid carcinoma. Am. J. Pathol. 83: 177, 1976.Google Scholar
  118. 118.
    Tashjian A.H. Jr., Howland B.G., Melvin K.E.W, Hill C.S. Immunoassay of human calcitonin: clinical measurement, relation to serum calcium and studies in patients with medullary carcinoma. N. Engl. J. Med. 283: 890, 1970.Google Scholar
  119. 119.
    Hennessy J.F., Wells S.A. Jr., Ontjes D.A., Cooper C.W. A pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 39: 487, 1975.Google Scholar
  120. 120.
    Sizemore G.W., Go V.L.W. Stimulation tests for diagnosis of medullary thyroid carcinoma. Mayo Clin. Proc. 50: 53, 1975.PubMedGoogle Scholar
  121. 121.
    Mannelli M., Maggi M., De Feo M.L., Cuomo S., Forti G., Moroni F., Giusti G. Naloxone administration releases catecholamines. N. Engl. J. Med. 308: 654, 1983.PubMedGoogle Scholar
  122. 122.
    Mannelli M., Maggi M., De Feo M.L., Boscaro M., Opocher G., Mantero F., Baldi E., Giusti G. Opioid modulation of normal and pathological human chromaffine tissue. J. Clin. Endocrinol. Metab. 62: 577, 1986.PubMedGoogle Scholar
  123. 123.
    Hamilton B.P., Landsberg L., Levine R.J. Measurement of urinary epinephrine in screening for pheochromocytoma in multiple endocrine neoplasia type II. Am. J. Med. 65: 1027, 1978.PubMedGoogle Scholar
  124. 124.
    Gagel R.F., Tashjian A.H., Cummings T., Papathana-sopoulos N., Kaplan M.M., De Lellis R.A., Wolfe H.J., Reichlin S. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N. Engl. J. Med. 318: 478, 1988.PubMedGoogle Scholar
  125. 125.
    Telenius-Berg M., Adolfsson L., Berg B., Hamberger B., Nordenfeit I., Tibblin S., Welander G. Catecholamine release after exercise. A new provocative test for early diagnosis of pheochromocytoma in multiple endocrine neoplasia type 2. Acta Med. Scand. 222: 351, 1987.PubMedGoogle Scholar
  126. 126.
    Welch T.J., Sheedy P.F., Van Heerden J.A., Sheps S.G., Hattery R.R., Stephens D.M. Pheochromocytoma: value of computed tomography. Radiology 148: 501, 1983.PubMedGoogle Scholar
  127. 127.
    Francis I.R., Glazer G.M., Shapiro B., Sisson J.C., Gross B.H. Complementary roles of CT and |131-MIBG scintigraphy in diagnosing pheochromocytoma. A.J.R. 141: 719, 1983.Google Scholar
  128. 128.
    Quint L.E., Glazer G.M., Francis I.R., Shapiro B., Chenevert T.L. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and |131 MIBG scintigraphy. Radiology 165: 89, 1987.PubMedGoogle Scholar
  129. 129.
    Wieland D.M., Wu J.I., Brown L.E., Mangner T.J., Swanson D.P, Beierwaltes W.H. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with 131-l-iodobenzylguanidine. J. Nucl. Med. 21: 349, 1980.PubMedGoogle Scholar
  130. 130.
    Sisson J.C., Frager M.S., Valk T.W., Gross M.D., Swanson D.P., Wieland D.M., Tobes M.C., Beierwaltes W.H., Thompson N.W. Scintigraphic localization of pheochromocytoma. N. Engl. J. Med. 305: 12, 1981.PubMedGoogle Scholar
  131. 131.
    Fischer M., Vetter W., Winterberg B., Hengstmann J., Zidek W., Friemann J., Vetter H. Scintigraphic localization of pheochromocytomas. Clin. Endocrinol. 20: 1, 1984.Google Scholar
  132. 132.
    Chatal J.F., Charbonnel B. Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma. J. Clin. Endocrinol. Metab. 61: 769, 1985.PubMedGoogle Scholar
  133. 133.
    Cheung P.S.Y., Thompson N.W., Dmuchowski C.F., Sisson J.C. Spectrum of pheochromocytoma in the 131 -l-MIBG era. World J.Surg. 12: 546,1988.PubMedGoogle Scholar
  134. 134.
    Ackery D.M., Tippett P.A., Condon B.R., Sutton H.E., Wyeth P. New approach to the localisation of pheochromocytoma: imaging with iodine-131-meta-iodo-benzyl-guanidine. Br. Med. J. 288: 1587, 1984.Google Scholar
  135. 135.
    Sutton H., Wyeth P., Allen A.P., Thurttle O.A., Hames T.K., Cawley M.I.D., Ackery D. Disseminated malignant pheochromocytoma: localization with iodine-131-labelled meta-iodobenzylguanidine. Br. Med. J. 285: 1153, 1982.Google Scholar
  136. 136.
    Stewart R.J., Anderson J.R., Laird J.D., Atkinson A.B., Kennedy T.L. Meta-iodobenzylguanidine in metastatic pheochromocytoma. Clin. Endocrinol. 21: 525, 1984.Google Scholar
  137. 137.
    Thompson N.W., Allo M.D., Shapiro B., Sisson J.C., Beierwaltes W. Extra-adrenal and metastatic pheochromocytoma: the role of 131-l-meta-iodobenzylguanidine (131-I-MIBG) in localization and management. World J. Surg. 8: 605, 1984.PubMedGoogle Scholar
  138. 138.
    Shapiro B., Sisson J.C., Mangner T., Wieland D., Gross M.D., Copp J., Eyre P., Beierwaltes W.H. Experience with 131-l-MIBG scintigraphy in the location of pheochromocytoma. Eur. J. Nucl. 8: A2, 1984 (abstract).Google Scholar
  139. 139.
    Brown M.J., Fuller R.W., Lavender J.P. False diagnosis of bilateral pheochromocytoma by iodine-131-labelled MIBG. Lancet i: 56, 1984.Google Scholar
  140. 140.
    Ackery D., Tippet P., Harley A., Weinkove C. False positive diagnosis of pheochromocytoma with I-131-MIBG scintigraphy. Lancet i: 733, 1984.Google Scholar
  141. 141.
    Von Moll L., McEwan A.J., Shapiro B., Sisson J.C., Gross M.D., Lloyd R., Beals E., W.H., Thompson N.W. Lodine-131 -MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J. Nucl. Med. 28: 979, 1987.Google Scholar
  142. 142.
    Beierwaltes W.H. A new method of identifying pheochromocytoma and providing that a “mass” is a “pheo”. J. Urol. 134: 105, 1985.PubMedGoogle Scholar
  143. 143.
    Lenhert H., Weber P., Naegele-Woehrle B., v. Buelow M., Eissner D., Schweden F., Jungingen Th., Schrezenmeir J., Krause U., Beyer J. Intraoperative localisation of malignant pheochromocytoma by 123-l-metaiodobenzylguanidine single probe measurement. Klin. Wochenschr. 66: 61, 1988.Google Scholar
  144. 144.
    Shulkin B.L., Shapiro B., Francis I.R., Dorr R., Shen S.W., Sisson J.C. Primary extra-adrenal pheochromocytoma. Positive I-123-MIBG imaging with negative I-131-MIBG imaging. Clin. Nucl. Med. 11: 851, 1986.PubMedGoogle Scholar
  145. 145.
    Bomanji J., Levison D.A., Flatman W.D., Home T., Bouloux P.M.-G., Ross G., Britton K.E., Besser G.M. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas and neuroblastomas: a histopatho-logical comparison. J. Nucl. Med. 28: 973, 1987.PubMedGoogle Scholar
  146. 146.
    Valk T.W., Frager M.S., Gross M.D., Sisson J.C., Wieland D.M., Swanson D.P., Mangner Y.J., Beierwaltes W.H. Spectrum of pheochromocytoma in multiple endocrine neoplasia. Ann. Intern. Med. 94: 762, 1981.PubMedGoogle Scholar
  147. 147.
    Jansson S., Tissel L.E., Fjaelling M., Lindberg S., Jacobsson L., Zachrisson B.F. Early diagnosis and surgical strategy for adrenal medullary disease in MEN II gene carriers. Surgery 103: 11, 1988.PubMedGoogle Scholar
  148. 148.Yobbagy
    J.J., Levatter R., Sisson J.C., Shulkin B.L., Polley T. Scintigraphic portrayal of the syndrome of multiple endocrine neoplasia type-2B. Clin. Nucl. Med. 13: 433, 1988.Google Scholar
  149. 149.
    Falke T.H.M., Strake L., Shaff M.I., Sandler M.P, Kulkarin M.V., Partain C.L., Nieuwenhuisen-Kruseman A.C., James A.E. Jr.. MR imaging of the adrenals: correlation with computed tomography. J. Comput. Assist. Tomogr. 10: 242, 1986.PubMedGoogle Scholar
  150. 150.
    Reinig J.W., Doppman J.L., Dwyer A.J., Johnson A.R., Knopp R.H. Adrenal masses differentiated by MR. Radiology 158: 81, 1986.PubMedGoogle Scholar
  151. 151.
    Schmedtje J.F., Sax S., Pool J.L., Goldfarb R.A., Nelson E.B. Localization of ectopic pheochromocytomas by magnetic resonance imaging. Am. J. Med. 83: 770, 1987.PubMedGoogle Scholar
  152. 152.
    Dunnick N.R. CT and MRI of adrenal lesions. Urol. Radiol. 10: 12, 1988.PubMedGoogle Scholar
  153. 153.
    Chezmar J.L., Robbins S.M., Nelson R.C., Steinberg H.V., Torres W.E, Bernardino M.E. Adrenal masses: characterization with T1-weighted MR imaging. Radiology 166: 357, 1988.PubMedGoogle Scholar
  154. 154.
    Juliani G., Avataneo T., Potenzani F. La tomografia a RM nella patologia surrenalica. Rapporto su 25 casi controllati istologicamente. Radiol. Med. 75: 515, 1988.PubMedGoogle Scholar
  155. 155.
    Von Euler U.S., Genzell C.A., Stroem G., Westman A. Report of a case of pheochromocytoma with special regard to preoperative diagnostic problems. Acta Med. Scand. 153: 127, 1955.Google Scholar
  156. 156.
    Von Euler U.S., Stroem G. Present status of diagnosis and treatment of pheochromocytoma. Circulation 15: 5, 1957.Google Scholar
  157. 157.
    Crout J.R., Sjoerdsma A. Catecholamines in the localization of pheochromocytoma. Circulation 22: 516, 1960.PubMedGoogle Scholar
  158. 158.
    Vendsalu A. Studies on adrenaline and noradrenaline in human plasma. Acta Physiol. Scand. 49 (Suppl. 173): 78, 1960.Google Scholar
  159. 159.
    Mahoney E.M., Friend D.G., Dexter L., Harrison J.H. Localization of adrenal and extra-adrenal pheochromocytoma by vena cava blood sampling. S. Forum 14: 495, 1963.Google Scholar
  160. 160.
    McGuire L.B., Fox L.M. Recurrent pheochromocytoma with recognition of site of metastasis by means of venous catheterization. Ann. Intern. Med. 60: 125, 1964.PubMedGoogle Scholar
  161. 161.
    Fleisher D.S., Voci G., Cresson S.L., Karatin L. Preoperative localization of pheochromocytoma. J. Pediatr. 64: 711, 1964.PubMedGoogle Scholar
  162. 162.
    Duke W.W., Boshell B.R, Soteres P., Carr J.H. A norepinephrine-secreting glomus jugulare tumor presenting as a pheochromocytoma. Ann. Intern. Med. 60: 1040, 1964.Google Scholar
  163. 163.
    Grim C.E., Glenn J.F., Wynn J.O., Gunnells J.C. Bilateral pheochromocytoma: the application of a plasma catecholamine bioassay for tumor localization. Am. Heart J. 74: 809, 1967.PubMedGoogle Scholar
  164. 164.
    Harrison T.S., Seaton J.F., Cerny J.C., Bookstein J.J., Bartlett J.D. Localization of pheochromocytoma by caval catheterization. Arch. Surg. 95: 339, 1967.PubMedGoogle Scholar
  165. 165.
    Mahoney E.M., Crocker D.W., Friend D.G., Dexter L., Skillman J.J., Harrison J.H. Adrenal and extra-adrenal pheochromocytomas: localization by vena cava sampling and observations on renal juxtaglomerular apparatus. J. Urol. 108: 4, 1972.PubMedGoogle Scholar
  166. 166.
    Harrison T.S., Freier D.T. Pitfalls in the technique and interpretation of regional venous sampling for localizing pheochromocytoma. Surg. Clin. North Am. 54: 339, 1974.PubMedGoogle Scholar
  167. 167.
    Jones D.H., Allison D.J, Hamilton C.A., Reid J.L. Selective venous sampling in the diagnosis and localization of pheochromocytoma. Clin. Endocrinol. 10: 179, 1979.Google Scholar
  168. 168.
    Moss S., Greenbaum R., Sever P.S. Preoperative localization of a pheochromocytoma using plasma noradrenaline concentrations in multiple-site samples. J. Royal Soc. Med. 73: 139, 1980.Google Scholar
  169. 169.
    Dunnick N.R., Doppman J.L., Gill J.R., Strott C.A., Keiser H.R., Brennan M.F. Localization of functional adrenal tumors by computed tomography and venous sampling. Radiology 142: 429, 1982.PubMedGoogle Scholar
  170. 170.
    Snell M.E., Lawrence R., Sutton D., Sever P.S., Peart W.S. Advances in the techniques of localisation of adrenal tumours and their influence on the surgical approach to the tumour. Br. J. Urol. 55: 617, 1983.PubMedGoogle Scholar
  171. 171.
    Mannelli M., De Feo M.L., Maggi M. II feocromocitoma. Aggiornamento del Medico 8: 320, 1985.Google Scholar
  172. 172.
    Mannelli M, Gheri R.G., Selli C., Turini D., Pampanini A., Giusti G., Serio M. A study on human adrenal secretion. Measurement of epinephrine, norepinephrine dopamine and cortisol in peripheral and adrenal venous blood under surgical stress. J. Endocrinol. Invest. 5: 91, 1982PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1989

Authors and Affiliations

  • M. Mannelli
    • 1
  1. 1.Endocrinology Service USL 10/D, Endocrinology UnitUniversity of FlorenceFlorenceItaly

Personalised recommendations